Streamline Health Solutions Inc

Streamline Health Solutions Inc (STRM) Stock Analysis

$5.333

-0.007 (-0.13%)At close

Loading chart…
High
5.335
Open
5.335
VWAP
5.33
Vol
4.06K
Mkt Cap
29.77M
Low
5.330
Amount
21.63K
EV/EBITDA, TTM
10.81

Streamline Health Solutions, Inc. enables healthcare organizations to proactively address revenue leakage and improve financial performance. The Company delivers integrated solutions, technology-enabled services and analytics. It operates in one segment as a provider of health information technology solutions and associated services that improve healthcare processes and information flows within a healthcare facility. It sells its solutions and services in North America to hospitals and health systems through its direct sales force and its reseller partnerships. It offers solutions and services to assist its clients in revenue cycle management, including its two flagship technologies: RevID and eValuator. RevID offers automated, daily reconciliation of clinical event activity to patient billing charge items prior to billing. eValuator provides 100% automated coding analysis prior to billing. In addition, it offers an array of professional services, including system implementation.

Analyst Ratings (3)

-6.25% downside
Hold
1 Buy
2 Hold
0 Sell
Current: 5.33
Low
5.00
Average
5.00
High
5.00

Lake Street

2025-12-02

Price Target

$8

Buy

Lake Street

2022-11-21

Price Target

$3

Strong Buy

Lake Street

2022-05-20

Price Target

$3

Strong Buy

Lake Street

2016-04-25

Price Target

Hold

Lake Street

2014-02-04

Price Target

$10

Strong Buy

Valuation Metrics

The current forward P/E ratio for Streamline Health Solutions Inc (STRM) is -1.86, compared to its 5-year average forward P/E of -5.30.

Forward P/E

Overvalued
5Y Average P/E
-5.30
Current P/E
-1.86
Overvalued
-2.54
Undervalued
-8.07

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-21.35
Current EV/EBITDA
10.81
Overvalued
55.65
Undervalued
-98.35

Forward P/S

Undervalued
5Y Average P/S
2.21
Current P/S
0.58
Overvalued
3.55
Undervalued
0.87

Alphio AI Price Scenarios for STRM

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%STRM

$2.37

Scenario price

B

Base

Base · 50%STRM

$1.94

Scenario price

B

Bear

Bear · 25%STRM

$1.65

Scenario price

Events Timeline

2025-06-16 (ET)

16:11:56

Streamline Health reports Q1 EPS (40c) vs. (71c) last year

2025-05-29 (ET)

08:06:23

Streamline Health to acquire MDaudit for $37.4M in cash

2025-05-01 (ET)

17:18:29

Streamline Health signs new contract for eValuator in Ohio

2025-01-15 (ET)

06:34:42

Streamline Health announces new eValuator contract with Deaconess Health

2024-12-18 (ET)

06:35:52

Streamline Health expands presence in Texas with 400-bed health system

News

STRM FAQ — answered by Alphio AI

Streamline Health Solutions, Inc. enables healthcare organizations to proactively address revenue leakage and improve financial performance. The Company delivers integrated solutions, technology-enabled services and analytics. It operates in one segment as a provider of health information technology solutions and associated services that improve healthcare processes and information flows within a healthcare facility. It sells its solutions and services in North America to hospitals and health systems through its direct sales force and its reseller partnerships. It offers solutions and services to assist its clients in revenue cycle management, including its two flagship technologies: RevID and eValuator. RevID offers automated, daily reconciliation of clinical event activity to patient billing charge items prior to billing. eValuator provides 100% automated coding analysis prior to billing. In addition, it offers an array of professional services, including system implementation. It operates in the Healthcare sector (SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN industry).

3 analysts cover STRM: 1 rate it Buy, 2 Hold and 0 Sell. The average price target is 5.00.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started